3rd Line and beyond

You are here

3rd Line and beyond

If you have been NEWLY DIAGNOSED  START HERE 

Video Library

Lung Cancer Video Library - Immunotherapy for Previously Treated Patients with NSCLC
Dr. Karen Reckamp, MD, MS, City of Hope Comprehensive Cancer Center in Duarte, California joined GRACE to discuss the role of immunotherapy for previously treated patients with non-small cell lung cancer.
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
3rd Line and beyond, Second-line treatment, Immunotherapies
,
,
Targeted Therapies in Lung Cancer Patient Forum 2017 - Presentations and Handouts
Download the speaker presentations and handouts from the Targeted Therapies Patient Forum in Cleveland at the Taussig Cancer Center on September 16, 2017.
Cancer Journey:
Just Diagnosed, In Treatment, Survivorship
Cancer Type:
Lung Cancer
Disease Learning:
General Lung Cancer, Tumor Marker Tests, 3rd Line and beyond, Targeted Therapy, Molecular Testing, First-line treatment, Scans - PET-CT, etc., Second-line treatment, Clinical Trials, Non Small Cell Lung Cancer
What are the Goals of Treating Advanced NSCLC?
Transcript I think there are several goals when treating a patient with advanced non-small cell lung cancer. For one I think we want to extend life,...
Cancer Journey:
In Treatment, Just Diagnosed
Cancer Type:
Lung Cancer
Disease Learning:
Chemotherapy, First-line treatment, Molecular Testing, Targeted Therapy, Maintenance Therapy, Symptoms, Second-line treatment, 3rd Line and beyond

Articles

ALK Inhibitors for Acquired Resistance: Zykadia and Alectinib
Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Targeted Therapy, Molecular Testing, Maintenance Therapy, Second-line treatment, 3rd Line and beyond
Combinations and Other Options for Acquired Resistance in EGFR Mutation-Positive NSCLC
Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Targeted Therapy, Chemotherapy, Molecular Testing, Maintenance Therapy, Radiation Therapy, Second-line treatment, 3rd Line and beyond
Panel Q&A Session on Acquired Resistance with Drs. Reckamp & Owonikoko
Dr. West moderates a question & answer session with Drs. Karen Reckamp and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.
Cancer Journey:
In Treatment, Just Diagnosed
Cancer Type:
Lung Cancer
Disease Learning:
Targeted Therapy, First-line treatment, Molecular Testing, Maintenance Therapy, Second-line treatment, 3rd Line and beyond
The Perils of Molecular Oncology: Mutations Aren't Everything, or at Least They're Not Infallible
Every few months I see a patient who reminds me of the fallability of mutation testing. One of the brightest rays of hope in the management of lung...
Cancer Journey:
In Treatment, Just Diagnosed
Cancer Type:
Lung Cancer
Disease Learning:
Targeted Therapy, Molecular Testing, Symptoms, Second-line treatment, 3rd Line and beyond
MARQUEE Trial of MET Inhibitor Tivantinib (ARQ-197) Negative for Survival Benefit, But OS Benefit Seen in MET-Positive Patients
Almost exactly a year ago, I reported that the large MARQUEE trial of EGFR inhibitor Tarceva (erlotinib) plus either the MET inhibitor tivantinib (...
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Targeted Therapy, Second-line treatment, 3rd Line and beyond

Community Forum

No Result Found